Tebentafusp-tebn (Kimmtrak, Immunocore) — the only FDA-approved treatment for this indication — is the first T-cell receptor therapeutic to receive regulatory approval.
Publications
FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma
The FDA has approved tebentafusp-tebn (Kimmtrak) for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma.
FDA grants fast track designation to BNT111 for advanced melanoma
BNT111 (BioNTech) — an investigational cancer immunotherapy — uses a fixed combination of mRNA-encoded, tumor-associated antigens designed to activate a precise and strong immune response against cancer.
Correlation of CCL8 expression with immune cell infiltration of skin cutaneous melanoma: potential as a prognostic indicator and therapeutic pathway
The tumor microenvironment (TME) is critical in the progression and metastasis of skin cutaneous melanoma (SKCM).